MAPT and Alzheimer disease: Klaver et al. tested the binding of IgG and IgM from AD, MCI, and control subjects to p-tau and tau, using as antigens 196-207 tau peptide, as well as full-length variants (tau and p-tau at Serine-199 and Serine-202).